Form 4: Dyne Therapeutics Executive Sells Shares to Cover Tax Obligations

Richard Scalzo, SVP at Dyne Therapeutics, sold 2,735 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Richard Scalzo, Senior Vice President, Head of Finance & Administration at Dyne Therapeutics, sold 2,735 shares of common stock on November 18, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units granted on November 15, 2023.
• The shares were sold at a weighted average price of $28.20, with individual transactions ranging from $28.00 to $28.60.
• Following the transaction, Scalzo still beneficially owns 95,833 shares, which includes 89,969 unvested restricted stock units.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any significant positive or negative sentiment. It is a neutral event.

Positives

• The sale was part of a pre-arranged plan to cover tax obligations, indicating no discretionary trading.
• The executive still holds a significant number of shares, showing continued alignment with the company's performance.

Risks

• While the sale was for tax purposes, any significant insider selling could be perceived negatively by the market.

Industry Context

This type of transaction is common for executives who receive stock-based compensation, and the sale is often pre-planned to cover tax liabilities.

Comparison to Industry Standards

• Similar sales by executives to cover tax obligations are common across the biotechnology industry.
• Many companies use restricted stock units as part of executive compensation packages, leading to similar tax-related sales.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Dyne Therapeutics, insider trading, stock sale, restricted stock units, tax obligations, Richard Scalzo, executive compensation